SRRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Sierra Oncology's Operating Income for the three months ended in Mar. 2022 was $-27.88 Mil. Sierra Oncology's Interest Expense for the three months ended in Mar. 2022 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies interest coverage is at least 5. Sierra Oncology Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Sierra Oncology's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Sierra Oncology's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Sierra Oncology Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||||||
Interest Coverage | Get a 7-Day Free Trial | No Debt | N/A | N/A | N/A | N/A |
Sierra Oncology Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Sierra Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sierra Oncology's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Sierra Oncology's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as
Here, for the fiscal year that ended in Dec. 2021, Sierra Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-94.59 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.49 Mil.
GuruFocus does not calculate Sierra Oncology's interest coverage with the available data. |
Sierra Oncology's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as
Here, for the three months ended in Mar. 2022, Sierra Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-27.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $5.30 Mil.
GuruFocus does not calculate Sierra Oncology's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Sierra Oncology (NAS:SRRA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Sierra Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | director, 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
William D. Turner | officer: Chief Reg & Tech Ops Officer | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Mary Christina Thomson | officer: General Counsel | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Joshua Richardson | director, 10 percent owner | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Longitude Prime Fund, L.p. | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Longitude Prime Partners, Llc | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Gaurav Aggarwal | director, 10 percent owner | C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Vivo Opportunity Fund, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Georgia Erbez | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
From GuruFocus
By Business Wire Business Wire • 01-25-2022
By Business Wire Business Wire • 01-18-2022
By Business Wire Business Wire • 01-27-2022
By Business Wire Business Wire • 02-03-2022
By Business Wire Business Wire • 05-26-2022
By Business Wire Business Wire • 01-27-2022
By Business Wire Business Wire • 02-18-2022
By GuruFocus Research GuruFocus Editor • 10-13-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 04-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.